Informing global polio eradication efforts through innovative modeling approaches
Forecast
Centers for Disease Control-GHC plans to offer grants to any type of organization. It expects to make one award worth $2.0 million in total. It is a forecast: the notice is expected around December 14, 2026, with applications due around February 12, 2027.
From the official notice on Grants.gov, last changed August 31, 2026. Checked October 31, 2026.
- Award ceilingnot stated
- Award floornot stated
- Expected awards1
- Total funding$2.0 million
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Forecast posted | August 31, 2026 |
|---|---|
| Expected posting | December 14, 2026 |
| Expected deadline | February 12, 2027 |
| Expected award date | August 1, 2027 |
Add the deadline to your calendar
Who can apply
This opportunity is open to any type of organization.
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
N/A
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
This NOFO will provide critical disease modeling to inform decision making on the development of strategies for cVDPV2 outbreak response, optimal surveillance upon global WPV eradication, and surveillance to detect containment breaches. It will also build capacity for a diverse public health workforce of statistical and mathematical modelers. Additionally, models will assess economic implications of outbreak response and surveillance strategies, while developing workforce capacity for students in statistical and mathematical modeling for polio and other VPDs.
How to apply
- Read the full notice and attachments on Grants.gov. The notice is the official source for deadlines and requirements.
- Make sure your organization has an active SAM.gov registration and Unique Entity ID; registration can take several weeks.
- Register on Grants.gov and submit through Workspace before the deadline and time given in the notice. Our application guide walks through each step.
Questions go to Julie Jenks, JJenks@cdc.gov, 404-718-2794.
Questions people ask
Who can apply for Informing global polio eradication efforts through innovative modeling approaches?
Centers for Disease Control-GHC accepts applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Informing global polio eradication efforts through innovative modeling approaches?
Expected deadline February 12, 2027. Confirm the date and time in the official notice on Grants.gov.
How much funding is available?
About $2.0 million in total for one award.
Similar open grants
- Continuation of the Collaborative Islet Transplantation Registry (U01 Clinical Trial Not allowed)
- BRAIN Initiative Cell Atlas Network (BICAN): Coordinating Unit for Biostatistics, Informatics, and Engagement (CUBIE)
- Centers without Walls for mechanisms of neurodegeneration in Alzheimer’s disease-related dementias (ADRD)
- Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimer's Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets (U01 Clinical Trial Not Allowed)
- Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE, RP1 Clinical Trial Not Allowed)
- Exposomic Contributions to ADRD Pathology and Resilience